Several studies have been published on the relation between oral contraceptives (OC) and cancers of the breast and of the female genital tract, mostly conducted in North America or Britain. In general, they give suggestive evidence that oral contraceptives may confer protection against cancers of the endometrium (Kaufman et al., 1980; Centers for Disease Control Cancer and Steroid Hormone Study, 1983c) and of the ovary (Centers for Disease Control Cancer and Steroid Hormone Study, 1983b; Newhouse et al., 1977; Rosenberg et al., 1982; Weiss et al., 1981) . The risk of cervical cancer for oral contraceptive users, on the other hand, was elevated in several studies (Harris et al., 1980; Kay, 1983; Vessey et al., 1983b ; WHO Collaborative Study of Neoplasia and Steroid Contraceptives, 1985) : the overall estimate of the increased risk, however, was relatively limited, and it is difficult in such a situation to distinguish between a causal association and a confounding effect potentially due to differences in sexual habits (Franceschi et al., 1986) . With regard to breast cancer, various studies have shown elevated risks in subgroups with Correspondence: C. La Vecchia. Received 11 February 1986. positive family history of breast cancer (Brinton et al., 1982) , previous breast biopsy for benign conditions (Brinton et al., 1982; Fasal & Paffenbarger, 1975; Janerich et al., 1983) in women who had used oral contraceptives before birth of the first child (Pike et al., 1981) , or in young longterm users of oral contraceptives (Pike et al., 1983; McPherson et al., 1983) . These results, however, were often not confirmed by subsequent studies and there is at present little convincing evidence of any association between oral contraceptive use and breast cancer risk (Centers for Disease Control Cancer and Steroid Hormone Study, 1983a; Rosenberg et al., 1984; Vessey et al., 1983a; Hennekens et al., 1984; Stadel et al., 1985; Lipnick et al., 1986) .
In view of these uncertainties, and of the large public health importance of the issue, it may be of interest to consider the risk estimates for oral contraceptive use in further sets of data from different populations. In the present paper, we have summarized the interim results from a case-control study of cancers of the breast and of the female genital tract conducted in northern Italy. The data on ovanan cancer only have been partly published in a separate paper (La Vecchia et al., 1984a ).
Subjects and methods
Since 1979, we have conducted a case-control study of neoplasms of the female genital tract (ovary, endometrium and cervix); recruitment of breast cancer cases started in 1982. The design of this study has already been described (La Vecchia et al., 1984a, b, c) . Briefly, trained interviewers identify and question women admitted for the neoplasms under study and for a wide spectrum of other conditions to University and General Hospitals in the greater Milan area. On average, less than 2 per cent of the eligible women (cases or controls) refuse to be interviewed.
A standard questionnaire is used to obtain information on personal characteristics and habits, gynaecological and obstetric data, related medical history and history of lifetime use of oral contraceptives and other female hormones. The time and duration of use are recorded, as well as the brand name. Photographs of packages of the most common brands are provided to assist recall, whenever useful. The same questionnaire is used for cases of breast, ovarian and endometrial cancer, and their controls. For cases of cervical neoplasia and related controls, a detailed history of sexual habits and other variables of potential importance (e.g. history of cervical screening) is also elicited. The present paper is based on data obtained before November 30, 1985.
Cases
The cases studied were women with histologically confirmed cancers of the breast, ovary (epithelial only), endometrium and cervix (invasive) diagnosed within the year prior to inter-view, admitted to the National Cancer Institute, the Ospedale Maggiore of Milan (including the four largest teaching hospitals in Milan) and to the Obstetrics and Gynaecology Clinics of the University of Milan. The major control group (1,282 patients) was compared in turn with cases of breast, ovarian and endometrial cancer. On account of the different age distributions of the three case series and of the control group, age (in decades) was allowed for all analysis purposes. Of these control subjects, 33% had been admitted because of traumatic conditions, 24% for non-traumatic orthopaedic disorders (mostly low back pain and disc disorders), 15% for surgical conditions (mostly abdominal, such as acute appendicitis or strangulated hernia), and 28% for other illnesses such as eye, ear, nose and throat, and teeth disorders.
Controls for invasive cervical cancer, whose information was collected on a modified questionnaire (see above) were individually matched with cases for age in decades. Among them (225 patients), 28% had traumatic conditions, 30% were admitted for non-traumatic orthopaedic disorders, 21% for acute surgical diseases, and 21% for other conditions (eye. ENT, etc.).
The control group for subjects with CIN consisted of women (n = 202) found to have normal cervical smears at the same screening clinics where CIN subjects had been identified. They were also matched with cases for age in decades.
Data analysis and control of confounding We computed the odds ratios (as estimators of the relative risks), together with their 95% approximate confidence intervals (CI) of various cancers among women who had used combination oral contraceptives relative to women who had never used them (Breslow & Day, 1980) . Tests for linear trend in risk, where appropriate, were done by the method given by Mantel (1963) .
Decade of age was allowed for in all analyses by the Mantel-Haenszel procedure (Mantel & Haenszel, 1959 (Breslow & Day, 1980 (Table III) , whereas the point estimates tended to be below unity for shorter latency or recency intervals and, symmetrically, above unity for longer intervals (Table IV) . Finally, the point estimates were not materially heterogeneous in various strata of age (including women below age 40, where the relative risk was 0.87 with 95% CI=0.56-1.36), or parity (Table V) .
Cancer of the ovary thirty nine (9.6%) women with epithelial ovarian cancer had at one time used combination oral contraceptives. The relative risk for ever versus never use was 0.68 (95% CI=0.48-0.97) when only age was allowed for and 0.65 (95% CI=0.42-0.96) when allowance was made for all identified potential confounding factors (Table II) . The risk of ovarian cancer decreased with increasing duration of use, the point estimates declining to 0.52 for women who had used oral contraceptives for more than two years. This trend in risk was statistically significant (Table III) .
The protection appeared to be long lasting, since the risk estimates remained below unity several years after first (RR=0.83 for 10 or more years) or last (RR= 0.75 for 5 or more years) OC use (Table  IV) . Likewise, the decreased risk of ovarian cancer among ever users was consistent across strata of age or parity (Table V) .
Cancer of the endometrium Combination oral contraceptives had been used by only seven (4.1%) endometrial cancer cases. This, of course, should be considered in the light of the relatively older age of women with the cancer of the corpus uteri, over 70% of the cases being aged 50 to 59. The estimated relative risk for ever use, though considerably below unity (age-adjusted RR = 0.50), did not reach formal statistical significance (Table II) . The low number of OC users among cases precluded any further analysis of sub-groups.
Invasive cancer of the cervix uteri There were 43 (19.1%) women with invasive cervical cancer and 32 (14.2%) age-matched controls who had at one time used combination oral contraceptives. The age-adjusted relative risk was 1.49 (95% CI=0.88-2.55) and increased to 1.74 when allowance was made for several potential confounding factors (including rather detailed information on sexual habits) by means of multiple logistic regression (Table II) . The risk estimate was higher (RR = 2.94) for >2 year duration of use, and this test for linear trend was statistically significant (Table III) . However, the relative risks were slightly greater for women who had first used oral contraceptives less than ten years prior to diagnosis or interview or last used them less than five years before. The interactions with reference to latency and recency of use, however, were far from significant, and may easily be due to chance.
No important difference was evident in various strata of age or parity considered (Table V) .
Cervical intra-epithelial neoplasia Ever use or oral contraceptives was reported by 71 (35.1%) cases of cervical intra-epithelial neoplasia and 82 (40.6%) age matched controls, giving a relative risk estimate of 0.77 (95% CI=0.50-1.18). Adjustment for all identified potential confounding factors did not materially change this estimate (multivariate RR=0.69, Table II ).
The point estimates remained slightly (and not significantly) below unity when various levels of duration, latency or recency were considered (Tables III and IV) , and (for ever OC use) in most strata of age or parity analysed (Table V) .
Discussion
In the present study, women who used combination oral contraceptives appeared to experience a substantially reduced risk of epithelial ovarian cancer or cancer of the corpus uteri, whereas no association emerged between oral contraceptives and cancer of the breast. The risk of invasive. cervical cancer was elevated in women who had used oral contraceptives for longer than two years. However, there was little consistent relation with latency or recency of use for invasive cervical cancer, and no overall association with pre-invasive conditions.
The Study, 1983a,b,c; Rosenberg et al., 1984) . The larger proportion of ever users (-40%) anmong the present outpatient comparison group for cervical intraepithelial neoplasia is obviously due to the younger age of these subjects (median age =37 years) and, possibly, to their selection criteria, since more educated and higher social class women in Italy tend to use oral contraceptives more commonly an'd, as expected, preferentially attend screening clinics (La Vecchia et al., 1984b ). These subjects, in any case, were compared with cases of pre-invasive conditions identified in the same outpatients screening clinics. Furthermore, average duration of use was considerably shorter in the present Italian population, since only about 5% of the inpatient comparison group and 16% of outpatient controls had used combination oral contraceptives for more than two years.
Thus, the absence of association between oral contraceptive use and the risk of breast cancer might be attributed to the low power of the present study. It is therefore of interest, within the overall design of the study, that the negative associations with ovarian (Newhouse et al., 1977; Rosenberg et al., 1982; Centers for Disease Control Cancer and Steroid Hormone Study, 1985b) or endometrial (Kaufman et al., 1980 ; Centers for Disease Control Cancer and Steroid Hormone Study, 1983c) cancers previously reported in several studies conducted in different populations were consistently confirmed in the present data.
Moreover, in American or British data as well there is little consistent evidence of a positive association between oral contraceptive use and breast cancer risk, though various studies reported elevated relative risks in specific subgroups (Fasal & Paffenbarger, 1975; Brinton et al., 1982; Janerich et al., 1983) .
With regard to cervical neoplasia, the present results can hardly be considered at variance with previous general evidence. In fact, the pooled relative risk for cervical abnormalities (mostly displasia or in situ carcinoma) from seven casecontrol studies or prospective investigations analysed as case-controls conducted in North America, Britain and Czechoslovakia (Thomas, 1972; Worth and Boyes, 1972; Boyce et al., 1977; Ory et al., 1977; Harris et al., 1980; Vonka et al., 1984 ; WHO Collaborative Study on Neoplasia and Steroid Contraceptives, 1985) and based on a total of over 20,000 subjects was 1.1 (Franceschi et al., 1986) thus indicating no or a very limited material overall elevation of risk in oral contraceptives users. It may also of interest to note that, in the present study, women who had ever used oral contraceptives did not have a larger number of sexual partners than those using other or no contraceptive method, but they did report more frequent screening 'Pap' smears, which have been reported to reduce risk of cervical cancer (La Vecchia et al., 1984b) . Although the overall risk estimate for invasive cervical cancer among ever OC users was only slightly and insignificantly elevated, and the relative risk for intraepithelial neoplasia was below unity, a significantly elevated invasive cancer risk was evident among women who had used oral contraceptives for over two years. This evidence, however, based on limited absolute numbers, is consistent with recent data from various other countries (WHO Collaborative Study of Neoplasia and Steroid Contraceptives, 1985; Brinton et al., 1985) .
In conclusion, the results of this study provide further reassurance on the relation between oral contraceptive use and cancers of the breast, ovary and endometrium, since in a population with broadly different general characteristics and contraceptive use patterns they confirm the negative association with ovarian or endometrial cancer risk previously reported mostly in American data. Furthermore, they indicate that the past or current pattern of oral contraceptive use in Italy is unlikely materially to affect the risk of breast cancer. Although the present data are clearly of little help in evaluating long-term use of oral contraceptives, or their potential effects on cancer risk after long latent intervals, the elevated invasive cervical cancer risk among long term users is clearly worrying and warrants further investigation on large sets of data.
